4BIO Capital
Venture capital for early-stage advanced therapies: cell, gene and RNA-based therapy, targeted therapies and microbiome
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- Biotech & Life Sciences, Hardware & Robotics
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Website
- 4biocapital.com
4BIO Capital is a London-based venture capital firm that invests in early-stage life sciences companies developing advanced therapies for conditions with high unmet medical need. Its strategy covers five modalities: RNA-based therapy, gene therapy, cell therapy, targeted therapies and the microbiome.
The firm places emphasis on social impact alongside returns. 4BIO Capital is the trading name of 4BIO Partners LLP, which is authorised and regulated by the Financial Conduct Authority, and it is a member of the BVCA.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.